NCT05616221: A trial that was reported late by Armata Pharmaceuticals, Inc.
This trial has reported, although it was 89 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05616221 |
|---|---|
| Title | A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 10, 2023 |
| Completion date | July 17, 2024 |
| Required reporting date | July 17, 2025, midnight |
| Actual reporting date | Oct. 14, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 89 |